Patents by Inventor Diane Lejeune

Diane Lejeune has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Method for identifying a substance which mediates interaction between interleukin 22 and an interleukin 22 receptor
    Patent number: 7846652
    Abstract: Interleukin-22 interacts with its receptor, referred to as IL-22R, and instigates a series of reactions, leading to activation of various molecules, such as JAK-1, Tyk2, and others. One can identify molecules which mediate this interaction by measuring the activity of one or more of the molecules in the pathway, to identify agonists and antagonists. These, in turn, are useful therapeutic agents, where inappropriate expression of one of the activated molecules is at issue, and requires amelioration.
    Type: Grant
    Filed: July 24, 2006
    Date of Patent: December 7, 2010
    Assignee: Wyeth
    Inventors: Jean-Christophe Renauld, Diane Lejeune, Laure Dumoutier
  • Method for influencing kinase pathways with IL-22
    Publication number: 20060257408
    Abstract: Interleukin-22 interacts with its receptor, referred to as IL-22R, and instigates a series of reactions, leading to activation of various molecules, such as JAK-1, Tyk2, and others. One can identify molecules which mediate this interaction by measuring the activity of one or more of the molecules in the pathway, to identify agonists and antagonists. These, in turn, are useful therapeutic agents, where inappropriate expression of one of the activated molecules is at issue, and requires amelioration.
    Type: Application
    Filed: July 24, 2006
    Publication date: November 16, 2006
    Inventors: Jean-Christophe Renauld, Diane Lejeune, Laure Dumoutier
  • Method for influencing kinase pathways with IL-22
    Publication number: 20030012788
    Abstract: Interleukin-22 interacts with its receptor, referred to as IL-22R, and instigates a series of reactions, leading to activation of various molecules, such as JAK-1, Tyk2, and others. One can identify molecules which mediate this interaction by measuring the activity of one or more of the molecules in the pathway, to identify agonists and antagonists. These, in turn, are useful therapeutic agents, where inappropriate expression of one of the activated molecules is at issue, and requires amelioration.
    Type: Application
    Filed: July 26, 2002
    Publication date: January 16, 2003
    Inventors: Jean-Christophe Renauld, Diane Lejeune, Laure Dumoutier